ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176
ASP Isotopes (NASDAQ: ASPI) has successfully commissioned its first Quantum Enrichment laser system in Pretoria, South Africa, and begun producing commercial samples of Ytterbium-176. The facility, completed in 8 months instead of the planned 18 months, represents the company's third enrichment facility in South Africa and first using Quantum Enrichment technology.
The company expects to achieve 99.75% enrichment for Ytterbium-176 and begin commercial sales in 2025. This isotope is important for producing Lutetium-177, used in oncology drugs like Novartis' Pluvicto, which has a market forecast exceeding $4 billion.
Following this success, ASPI is accelerating plans to construct facilities for Nickel-64, Gadolinium-160, and Lithium-6/7 enrichment. The company is also pursuing discussions with nuclear authorities regarding HALEU uranium enrichment facilities, addressing an estimated supply shortage of 3,000 metric tons by 2035, with potential customer demand valued at over $37 billion.
ASP Isotopes (NASDAQ: ASPI) ha commissionato con successo il suo primo sistema laser di arricchimento quantistico a Pretoria, Sudafrica, e ha iniziato a produrre campioni commerciali di Ytterbium-176. L'impianto, completato in 8 mesi invece dei 18 mesi previsti, rappresenta il terzo impianto di arricchimento dell'azienda in Sudafrica e il primo a utilizzare la tecnologia di arricchimento quantistico.
L'azienda prevede di raggiungere un arricchimento del 99,75% per l'Ytterbium-176 e di iniziare le vendite commerciali nel 2025. Questo isotopo è importante per la produzione del Lutetium-177, utilizzato in farmaci oncologici come il Pluvicto di Novartis, che ha una previsione di mercato superiore ai 4 miliardi di dollari.
Dopo questo successo, ASPI sta accelerando i piani per costruire impianti per l'arricchimento di Nickel-64, Gadolinium-160 e Lithium-6/7. L'azienda sta anche portando avanti discussioni con le autorità nucleari riguardo agli impianti di arricchimento di uranio HALEU, affrontando una stima di carenza di fornitura di 3.000 tonnellate metriche entro il 2035, con una potenziale domanda da parte dei clienti valutata oltre i 37 miliardi di dollari.
ASP Isotopes (NASDAQ: ASPI) ha puesto en marcha con éxito su primer sistema láser de enriquecimiento cuántico en Pretoria, Sudáfrica, y ha comenzado a producir muestras comerciales de Ytterbium-176. La instalación, completada en 8 meses en lugar de los 18 meses previstos, representa la tercera instalación de enriquecimiento de la empresa en Sudáfrica y la primera que utiliza tecnología de enriquecimiento cuántico.
La empresa espera lograr un enriquecimiento del 99,75% para el Ytterbium-176 y comenzar las ventas comerciales en 2025. Este isótopo es importante para la producción de Lutetium-177, que se utiliza en medicamentos oncológicos como Pluvicto de Novartis, que tiene una previsión de mercado que supera los 4 mil millones de dólares.
Tras este éxito, ASPI está acelerando sus planes para construir instalaciones de enriquecimiento de Nickel-64, Gadolinium-160 y Lithium-6/7. La empresa también está llevando a cabo conversaciones con las autoridades nucleares sobre las instalaciones de enriquecimiento de uranio HALEU, abordando una estimación de escasez de suministro de 3.000 toneladas métricas para 2035, con una demanda potencial de clientes valorada en más de 37 mil millones de dólares.
ASP Isotopes (NASDAQ: ASPI)는 남아프리카 프리토리아에 첫 번째 양자 농축 레이저 시스템을 성공적으로 가동하고 Ytterbium-176의 상업 샘플 생산을 시작했습니다. 이 시설은 계획된 18개월 대신 8개월 만에 완료되었으며, 회사의 남아프리카 세 번째 농축 시설이자 양자 농축 기술을 사용하는 첫 번째 시설입니다.
회사는 Ytterbium-176에 대해 99.75%의 농축을 달성하고 2025년에 상업 판매를 시작할 것으로 예상하고 있습니다. 이 동위 원소는 노바르티스의 Pluvicto와 같은 종양학 약물에 사용되는 Lutetium-177 생산에 중요합니다. 이 시장은 40억 달러를 초과할 것으로 예상됩니다.
이 성공에 따라 ASPI는 Nickel-64, Gadolinium-160, 및 Lithium-6/7 농축 시설 건설 계획을 가속화하고 있습니다. 또한 2035년까지 3,000 미터톤의 공급 부족을 해결하기 위해 HALEU 우라늄 농축 시설에 관한 원자력 당국과의 논의를 진행하고 있으며, 고객 수요 가치는 370억 달러를 초과할 것으로 예상됩니다.
ASP Isotopes (NASDAQ: ASPI) a réussi à mettre en service son premier système laser d'enrichissement quantique à Pretoria, en Afrique du Sud, et a commencé à produire des échantillons commerciaux de Ytterbium-176. L'installation, achevée en 8 mois au lieu des 18 mois prévus, représente la troisième installation d'enrichissement de l'entreprise en Afrique du Sud et la première utilisant la technologie d'enrichissement quantique.
L'entreprise s'attend à atteindre un enrichissement de 99,75% pour l'Ytterbium-176 et à commencer les ventes commerciales en 2025. Cet isotope est important pour la production de Lutetium-177, utilisé dans des médicaments oncologiques comme le Pluvicto de Novartis, dont les prévisions de marché dépassent 4 milliards de dollars.
Suite à ce succès, ASPI accélère ses plans de construction d'installations pour l'enrichissement de Nickel-64, Gadolinium-160 et Lithium-6/7. L'entreprise poursuit également des discussions avec les autorités nucléaires concernant des installations d'enrichissement d'uranium HALEU, afin de répondre à une pénurie d'approvisionnement estimée à 3 000 tonnes métriques d'ici 2035, avec une demande potentielle des clients évaluée à plus de 37 milliards de dollars.
ASP Isotopes (NASDAQ: ASPI) hat erfolgreich sein erstes Quantenanreicherungs-Lasersystem in Pretoria, Südafrika, in Betrieb genommen und mit der Produktion von kommerziellen Proben von Ytterbium-176 begonnen. Die Anlage wurde in 8 Monaten anstelle der geplanten 18 Monate fertiggestellt und stellt die dritte Anreicherungsanlage des Unternehmens in Südafrika dar, die erste, die die Quantenanreicherungstechnologie nutzt.
Das Unternehmen erwartet, ein 99,75% Anreicherung für Ytterbium-176 zu erreichen und 2025 mit dem kommerziellen Verkauf zu beginnen. Dieses Isotop ist wichtig für die Produktion von Lutetium-177, das in onkologischen Medikamenten wie Novartis' Pluvicto verwendet wird, dessen Marktprognose über 4 Milliarden Dollar hinausgeht.
Nach diesem Erfolg beschleunigt ASPI die Pläne zum Bau von Anlagen zur Anreicherung von Nickel-64, Gadolinium-160 und Lithium-6/7. Das Unternehmen führt auch Gespräche mit den nuklearen Behörden über HALEU-Urananreicherungsanlagen, um einen geschätzten Versorgungsengpass von 3.000 metrischen Tonnen bis 2035 zu adressieren, wobei die potenzielle Kundennachfrage auf über 37 Milliarden Dollar geschätzt wird.
- Successfully commissioned Quantum Enrichment facility ahead of schedule (8 months vs 18 months)
- Expected to achieve 99.75% enrichment for commercial Ytterbium-176 production in 2025
- Positioned as one of few Western suppliers of commercial Ytterbium-176
- Secured MOUs with US-based SMR companies including TerraPower for HALEU supply
- Addressing market opportunity of $37+ billion for HALEU supply
- Technology shows advantages in capital efficiency and reduced industrial pollution
- Faced unexpected technical challenges during commissioning phase
- Commissioning phase took longer than anticipated (6 months vs 3-6 months)
- Still requires regulatory approvals for HALEU uranium enrichment facilities
Insights
ASP Isotopes' successful commissioning of their Quantum Enrichment laser system marks a significant technological breakthrough in isotope production with implications across oncology and nuclear energy. The completion of this facility in just 8 months (versus an anticipated 18) demonstrates exceptional execution, despite commissioning challenges with OEM equipment.
Their achievement in producing commercial-grade Ytterbium-176 addresses a critical supply chain vulnerability in radiopharmaceuticals. Ytterbium-176 is essential for producing Lutetium-177, used in FDA-approved cancer drugs like Novartis' Pluvicto (projected
The proprietary Quantum Enrichment technology appears to offer three key advantages: efficiency, scalability, and capital efficiency. Being positioned as one of the few Western suppliers of these isotopes creates strategic importance beyond mere commercial opportunity.
The expansion into Nickel-64, Gadolinium-160, and Lithium-6/7 production reveals a well-conceived platform strategy. Particularly noteworthy is Lithium-6's critical role in fusion energy development and Lithium-7's applications in conventional and next-gen nuclear reactors. With no current commercial producer of Lithium-6 despite fusion companies targeting prototype devices in the 2030s, ASP stands to become an essential supplier in this emerging energy transition.
The potential application to HALEU production could be most consequential, addressing a projected 3,000-metric-ton supply shortage for next-generation small modular reactors. This positions ASP at the intersection of medical isotope production and nuclear energy security – both strategic priorities for Western nations.
ASP Isotopes' commissioning of their Quantum Enrichment facility represents a pivotal development for oncology treatment supply chains. The successful production of commercial-grade Ytterbium-176 directly addresses documented shortages in radiopharmaceutical precursors that have resulted in treatment delays of over two months for cancer patients.
The market timing is optimal. Lutetium-177-based therapies like Pluvicto have demonstrated clinical efficacy with two FDA-approved applications already and numerous ongoing trials. The radiopharmaceutical market's projected
ASP's positioning as potentially the only Western commercial supplier of Ytterbium-176 creates a strategic advantage. Healthcare systems increasingly seek supply chain resilience and diversification for critical materials, particularly those used in cancer treatments. The documented interest from customers across North America, Europe, and Asia validates the market need.
The technology platform's versatility across multiple isotopes (Ytterbium-176, Nickel-64, Gadolinium-160, and Lithium-6/7) creates multiple revenue pathways and reduces single-application risk. The copper-64 application in molecular radiotherapy and positron emission tomography expands their footprint in precision medicine, while the lithium isotopes open entirely different markets in energy production.
The accelerated construction timeline (8 months versus 18) demonstrates execution capability, though commissioning challenges suggest continued optimization will be required. ASP's existing relationships with research universities provide valuable scientific partnerships to support ongoing development. The milestone achieved represents not just technological validation but an important step toward addressing patient needs in oncology treatment.
- Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto.
- The Company expects to be able to achieve a
- The Company anticipates now being able to proceed with the plans to construct Nickel-64, Gadolinium-160 and Lithium-6/7 Quantum Enrichment facilities.
- The Company intends to continue its discussions with nuclear regulatory authorities for the authorization to construct HALEU uranium enrichment facilities using Quantum Enrichment in South Africa and other countries.
WASHINGTON, April 01, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has started the production of commercial samples of highly enriched Ytterbium-176, following the successful commissioning of the laser system at its first Quantum Enrichment facility in Pretoria, South Africa.
This is the Company’s third enrichment facility in South Africa and its first isotope enrichment facility to utilize Quantum Enrichment, a novel laser-based method of enrichment. The Company believes that this proprietary technology is not only more efficient and scalable than other enrichment technologies but also has considerable advantages with respect to capital efficiency and industrial pollution.
After a construction phase which lasted just 8 months, versus an anticipated timeline of 18 months, the commissioning phase took 6 months, versus an anticipated timeline of 3-6 months. The Company’s scientists overcame a number of unexpected challenges, including faults with OEM supplied time-of-flight mass spectrometers and vacuum pumps. The Company’s scientists continue to optimize various steps of the process but have overcome the major problems inherent in any new process and are successfully enriching Ytterbium-176 that will be suitable for commercial supply. The Company expects to be able to achieve a
“The success of this project is testament to the strong working relationship between our in-house scientists and technicians and the world class scientists in the fields of nuclear physics and laser technology that we are working with from our universities of Stellenbosch and Witwatersrand in South Africa,” said Hendrik Strydom, ASP Isotopes Inc.’s Chief Technology Officer.
Ytterbium-176 (176Yb) is a key stable isotope used in the production of Lutetium-177 (177Lu). Lutetium-177 is an emerging beta emitting radiopharmaceutical used in oncology drugs, such as Novartis’ Pluvicto. There are currently two FDA approved drugs and numerous ongoing clinical trials for drugs that require Lutetium-177.
Consensus forecasts for Novartis’ Pluvicto exceed
“Currently, there exist significant supply-side challenges for many essential radioisotopes used in various oncology treatments. We have received a considerable amount of interest from customers in North America, Europe and Asia for Ytterbium-176 and we look forward to easing supply chains and improving the quality of life for thousands of patients every year,” said Paul Mann, ASP Isotopes Inc.’s Executive Chairman and CEO.
Additional Planned Quantum Enrichment Plants – Nickel-64, Gadolinium-160 and Lithium-6/7
Based on the results of the commissioning phase of the Ytterbium-176 enrichment facility, the Company is now accelerating plans to construct Nickel-64 and Lithium-6/7 enrichment facilities in South Africa. The Company believes that there is an urgent need for all three isotopes from Western-based producers.
Nickel-64 is currently used to produce Copper-64, in a cyclotron, and based on discussions with potential customers, has significant supply-side challenges. Copper-64 is a positron and beta emitting isotope of copper, with applications for molecular radiotherapy and positron emission tomography.
Lithium-7 is currently used as an alkalizing agent for the coolant in Pressure Water Reactors (PWRs) and it is predicted that Lithium-7 will be used as part of the molten lithium fluoride in molten-salt reactors which are expected to become used in the nuclear energy industry next decade. Western supplies of Lithium-7 are currently provided by Russia.
It is widely anticipated that Lithium-6 will be required to enable nuclear fusion power plants, which are currently in development. It is widely anticipated that nuclear fusion will be one of the cleanest forms of energy, with potential for low carbon baseload energy with no long-lived radionuclide waste. There is currently no producer of Lithium-6 in commercial quantities, yet most power plant designs need tonnage of Lithium-6 for operations. With
Quantum Enrichment – A Novel Enrichment Technique Potentially Capable of Efficiently Producing Advanced Nuclear Fuels
The Company believes its Quantum Enrichment process will potentially also be able to produce HALEU (High Assay Low Enriched Uranium) at an attractive price, allowing new nuclear energy to become available at a “green discount” to carbon-intensive electricity production processes. This “green energy cost advantage” is expected to help accelerate the global adoption of new nuclear energy, with a corresponding benefit to climate goals.
HALEU will be required for use in the next generation of advanced nuclear reactors, such as SMRs (small modular reactors), that are now under development for commercial and government uses. Currently, there are no Western producers of HALEU in commercial quantities, and many SMR companies worldwide face substantial delays until this fuel supply issue is resolved. The Nuclear Energy Institute estimates that there may be a HALEU supply shortage of approximately 3,000 metric tons by 2035(3). However, based on discussions with and the interest received from potential customers, the Company believes this figure may be significantly larger.
The Company is in discussions with potential customers that anticipate requiring High Assay Low Enriched Uranium (HALEU), valued at over
| (1) | Lutetium-177 (Lu-177) Market Size, Scope And Forecast Report (marketresearchintellect.com) |
| (2) | Ravi et al, Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges; J Nuc Med March 2023, 64 (3) 349-350 |
| (3) | UK releases roadmap to quadruple nuclear energy capacity: Nuclear Policies - World Nuclear News (world-nuclear-news.org) |
| (4) | NEI-Letter-for-Secretary-Granholm_HALEU-2021.pdf |
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to, statements relating to the commencement of supply of isotopes to customers and the application of new technology for the enrichment of isotopes, the planned construction of additional isotope enrichment facilities, the future of the company’s enrichment technologies as applied to uranium enrichment, the outcome of the company’s initiative to commence enrichment of uranium in South Africa and the company’s discussions with nuclear regulators, and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including our reliance on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. “Risk Factors” of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company’s subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad – Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
FAQ
What is the expected timeline for ASP Isotopes (ASPI) to begin commercial Ytterbium-176 sales?
How long did it take ASPI to construct its Quantum Enrichment facility in Pretoria?
What is the market potential for ASPI's HALEU production?
Which new isotope production facilities is ASPI planning to construct?
What is the significance of ASPI's Ytterbium-176 production for the medical industry?
